You searched for "prostate cancer"
Factors and time to conversion from prostate cancer active surveillance to treatment
Active surveillance is the standard of care for men with low-risk and selected men with favourable intermediate risk prostate cancer. The aim is to reduce the morbidity and mortality of overtreatment of non-clinically significant prostate cancer. A significant proportion progress...
Prostate cancer mortality among elderly men after discontinuing organised screening
This study presents ground-breaking insights into discontinuing prostate cancer (PCa) screening in previously screened elderly men, aiming to mitigate the risk of overdiagnosis and overtreatment in the face of other-cause mortality. Examining men aged 70–74 who had undergone prostate specific...Prostate cancer spit test could save the NHS £500 million a year
Thousands of men could have their prostate cancer diagnosed at an earlier stage when it is easier and cheaper to treat, thanks to a new spit test which can be taken at home. An innovative new study launched this week,...Bupa covers accurate PSE prostate cancer blood test
A new era in prostate cancer detection is emerging with the EpiSwitch® PSE blood test, a highly accurate tool that enhances early diagnosis while significantly cutting false positives. Now covered by Bupa as a pre-biopsy test, PSE has demonstrated 94%...Micro-Ultrasound in Prostate Cancer: Diagnosis, risk stratification, and active surveillance
Prostate cancer diagnostics have undergone a major shift with the adoption of multiparametric MRI (mpMRI), improving detection of clinically significant disease while reducing unnecessary biopsies [1,2]. However, MRI-based pathways come with practical limitations: cost, access, delays and reliance on radiological...The role of specialist therapeutic radiographers in the treatment and care of men with prostate cancer
The Statement of Intent: Cancer Strategy for England: 2015-2020 indicates that the number of people diagnosed with cancer each year will continue to grow rapidly due to the ageing population. There is also a requirement to diagnose and offer patients...
Intermittent vs. continuous hormonal therapy for metastatic prostate cancer
Continuous androgen deprivation therapy (cADT) is the standard management for metastatic prostate cancer (mPCa). Intermittent androgen deprivation therapy (iADT) is sought to have better quality of life (QoL) and adverse events profile during off-treatment period. This multicentre European randomised study...Management of RHC in prostate cancer with selective embolisation and hyperbaric oxygen therapy
Prostate cancer is one of the most prevalent malignancies affecting men worldwide. Radiotherapy is a common treatment modality for localised and locally advanced prostate cancer. While radiotherapy can be effective, it may lead to complications such as radiation-induced haemorrhagic cystitis...Black men are more at risk from prostate cancer, but we won’t let it stay that way – an update from Prostate Cancer Research
- CHARITY FOCUS - Focusing on all of disease characteristics, societal factors, and better communication gives us real potential to fix a disparity that has persisted for too long. When it comes to health inequity, the numbers are stark. Black...
Is TRUS and biopsy obsolete as a diagnostic test for prostate cancer: refining the perineal biopsy technique?
Whilst there has been a dramatic shift in how patients are investigated for potential prostate cancer, transrectal ultrasound (TRUS) and biopsy remains the most commonly used technique for tissue sampling. In this single centre, retrospective analysis, 634 men, over a...
